This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Savaysa

Daiichi Sankyo Co., Ltd.

Drug Names(s): DU-176b, Lixiana (Japan)

Description: Edoxaban is an oral, direct inhibitor of blood coagulation factor Xa.

Deal Structure: Daiichi Sankyo and Daewoong Pharmaceutical
Daiichi Sankyo announced that its wholly owned subsidiary, Daiichi Sankyo Korea, and Daewoong Pharmaceutical have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA. No financial details were disclosed.

Daiichi Sankyo and Merck
In February 2016, Daiichi Sankyo announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group, has granted exclusive rights to Merck & Co, known as MSD outside the US and Canada to market the oral, once-daily anti-coagulant, LIXIANA (edoxaban), in 13 European countries: Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Romania, Slovakia, Slovenia and Sweden.

The aforementioned 13 countries are subject to the marketing authorization of the oral, once-daily anti-coagulant edoxaban which was obtained from the European Commission last June. Sales will proceed as soon as MSD completes launch...See full deal structure in Biomedtracker

Partners: Daewoong Pharmaceutical Company Ltd. Merck & Co., Inc. Les Laboratoires Servier


Savaysa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug